Different value-based payment approaches are evolving for different sorts of conditions, different sorts of financial circumstances, and other factors, explained Clifford Goodman, PhD, senior vice president and director, Center for Comparative Effectiveness Research, The Lewin Group.
This page contains sponsored advertising.
Different value-based payment approaches are evolving for different sorts of conditions, different sorts of financial circumstances, and other factors, explained Clifford Goodman, PhD, senior vice president and director, Center for Comparative Effectiveness Research, The Lewin Group.
Transcript
Has the move to value-based payments been happening as quickly as you expected?
With regard to the move toward value-based payments, it’s a couple interesting phenomena. One is that although most people might say that they’re disappointed in how quickly we’re moving to value-based payments, the very same people would probably say, “we didn’t realize how interesting and complex value-based payment is.”
So, although it seems to be taking some time, we’re also learning along the way. There’s no particular one right way to do value-based payment. Different value-based payment approaches are evolving for different sorts of conditions, different sorts of financial circumstances, and other factors are at work, as well. So, I would say that we are ramping up, but we’re learning how to do this piloting, experimenting, and getting feedback on what works.
In particular, some of the things that we’re noticing happen to be that it may be easy to conceptualize value-based payment, but how do you really operationalize it? Whose data are you going to use, how valid and rigorous are those data, who’s in charge of the data, who manages the data, who owns the data, and what sort of administrative burden is placed in the organization that’s charged with the data? And that’s just the data. So, again, overall ramping up gradually, but learning along the way. I’m still optimistic.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More